Calcitonin Gene-related Peptide Levels in Chronic Migraine

Status Completed

Clinical Trial Summary

Twenty patients will be enrolled in a 2-site, 7-month, double-blind study conducted to evaluate a reduction in headache days and attacks and calcitonin gene-related peptide (CGRP) levels in saliva following treatment with OnabotulinumtoxinA versus saline.

Eligible patients will be randomized and receive injections of OnabotulinumtoxinA or Saline at Visit 1. Following 3 months plus a 1 month wash out, patients will receive cross-over injections at Visit 5.

Patients will return for monthly visits and exit the study at Visit 8.

Patients will collect saliva at monthly intervals and document in a daily headache diary throughout the study .

Clinical Trial Description

This double-blind study will evaluate reduction in number of headache days following treatment with OnabotulinumtoxinA versus Saline. Additionally, CGRP levels in saliva will be correlated with a reduction in headache attacks.

At Visit 1, eligible subjects will be randomized 1:1 to receive injections of OnabotulinumtoxinA or Saline in an identical manner. Subjects will collect 3 saliva samples during each month of the 7 month study: 1 collection at Baseline headache level, 1 collection at onset of headache that is one degree worse than Baseline level that will be treated with acute therapy, and 1 collection at 2 hours following treatment. Subjects will document headache and headache symptoms in a daily diary and return to the clinic with diary and saliva samples at monthly visits.

Following 4 months (including a 1 month washout after Visit 4), subjects will return at Visit 5 and receive cross-over injections. Subjects randomized to OnabotulinumtoxinA at Visit 1 will receive injections of Saline. Subjects randomized to saline at Visit 1 will receive injections of OnabotulinumtoxinA. Subjects will document headache and headache symptoms in a daily diary and return to the clinic with diary and saliva samples at monthly visits.

At Visit 8, 3 months following re-injection at Visit 5, subjects will exit the study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01071096
Study type	Interventional
Source	Cady, Roger, M.D.
Contact
Status	Completed
Phase	Phase 4
Start date	June 2010
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05720819` - Biofeedback-VR for Treatment of Chronic Migraine	N/A
Not yet recruiting	`NCT06428838` - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context	Phase 3
Recruiting	`NCT05517200` - Pilot Study for a Machine Learning Test for Migraine
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Completed	`NCT02514148` - Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients	N/A
Enrolling by invitation	`NCT02291380` - A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine	Phase 3
Withdrawn	`NCT02122744` - RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine	N/A
Completed	`NCT02122237` - Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial	Phase 3
Recruiting	`NCT02202486` - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI	N/A
Completed	`NCT01709708` - Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine	Phase 4
Completed	`NCT01741246` - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging	N/A
Completed	`NCT01090050` - Treximet in the Treatment of Chronic Migraine	Phase 4
Recruiting	`NCT03507400` - Introvision for Migraine and Headaches	N/A
Completed	`NCT04161807` - Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine	N/A
Completed	`NCT03175263` - OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain	N/A
Withdrawn	`NCT04353505` - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache	Phase 1
Completed	`NCT01667250` - Non-Invasive Neurostimulation for the Prevention of Chronic Migraine	N/A
Completed	`NCT01700387` - A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency	Phase 4
Not yet recruiting	`NCT01135784` - Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache	Phase 2
Completed	`NCT00772031` - NINDS CRC Chronic Migraine Treatment Trial	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.